A Novel Candidate Tumor Suppressor and A Potential Prognostic Biomarker, Hvps52, in Gastric Cancer.

Jian Zhang,Xi-Chun Hu
DOI: https://doi.org/10.1200/jco.2016.34.15_suppl.e15537
IF: 45.3
2016-01-01
Journal of Clinical Oncology
Abstract:e15537 Background: The hVPS52 is a subunit of human GARP (Golgi associated retrograde protein) complex involved in retrograde transport from the early and late endosome to the late Golgi. Few transport proteins have been identified to play a role in anti-tumor effects. We sought to investigate the expression levels, mechanisms, and prognosis value of hVPS52 in primary gastric cancer. Methods: The protein expression of hVPS52 was investigated in various cancer cell lines including gastric, breast, lung, colon and liver cancers. The replication-deficient adenovirus expressing hVPS52 (Ad-hVPS52) and the control adenovirus (Ad-Vec) were constructed. Sixty-six paired cancerous and matched adjacent noncancerous gastric mucosa tissues with patient clinicopathological information were gathered in FUSCC for analysis. Results: Western blot and IHC staining data showed that hVPS52 expression was significantly decreased not only in gastric cancer cells (MGC80-3, BGC823), but also in gastric cancer tissue samples (positive rates in cancerous vs. noncancerous samples: 22.7% vs. 72.7%, p<0.001). The result also showed that the low hVPS52 expression was significantly correlated with later clinical stage (expression rate, stage III-IV vs. I-II: 8.8% vs. 37.5%, p = 0.018). Kaplan–Meier survival curves revealed that the reduced expression of hVPS52 was associated with a poor prognosis in gastric cancer patients (3-year OS, 50.6% vs. 86.2%, p = 0.013). The loss of heterozygosity of hVPS52 was found in 44.4% of cancerous tissues. Cell viability assay and crystal violet staining assay established the anti-tumor effect of hVPS52 overexpression via Ad-hVPS52. The marked apoptosis was observed when gastric cancer cells were infected by Ad-hVPS52 based on the TUNEL assay and flow cytometry. Cathepsin D/Bax/Cyto C/Caspase9/Caspase3 was identified as the main pathway to trigger the specific apoptosis. In vivo xenografted tumor model showed that hVPS52 overexpression significantly inhibited the growth of tumor. Conclusions: Our study suggests that hVPS52 might serve as a candidate tumor suppressor and a potential prognostic biomarker in gastric cancer, which provides a new anti-tumor strategy warranting further investigation.
What problem does this paper attempt to address?